Breaking the Cycle: The OCS Burden in CRSwNP

Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care. ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.  This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: Luong: Served on advisory boards for AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron; Consultant to Maxwell Biosciences, Medtronic and Stryker; Grant funding from Eli Lily and Sanofi. Cornet: Marjolein Cornet has received speaker fees and participated in advisory board meetings for Regeneron Pharmaceuticals Inc., Sanofi Genzyme, GSK, ALK, Mylan, Stallergenes Greer and Medtronic. © 2026 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2601160- 1.0 - 04/2026